Table 3.

Percentage of RA subjects achieving a normal humoral response^* 4 weeks after a 3rd dose of mRNA COVID-19 vaccine.

	All RA subjects (n = 60)	Held DMARDs around 3rd dose (n = 34)	Continued DMARDs around 3rd dose (n = 26)	p value+
Anti-S	43.3%	41.2%	46.2%	0.70
Anti-RBD	61.7%	70.6%	50.0%	0.10

Anti-S, anti-Spike. Anti-RBD, anti-receptor binding domain. DMARD, disease modifying anti-rheumatic drug.

^⁎Normal humoral response was defined as ELISA level at week 4 post-3rd dose within one standard deviation of the mean ELISA level in 50 healthy vaccinated controls 4–8 weeks after a 2nd dose (e.g., after completing the primary vaccine series for non-immunosuppressed adults).

⁺p values comparing subjects that held vs. continued DMARDs.